GRI Bio, Inc.
GRIHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune. The company carries a $3.2M market cap, placing it firmly in the micro-cap category. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Market Cap
$3.2M
Beta
-0.61
P/E (TTM)
—
P/E (Fwd)
-0.72
EPS (TTM)
$-14.92
EPS (Fwd)
$-2.00
ROE
-142.0%
ROA
-70.9%
Cash
$10.9M
Total Debt
$44,000
Free CF
-$6.6M
52W Change
-97.5%
Annual Financials
Cash vs Debt
Where GRI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GRI finished 27.50% below its 150-day moving average ($2.00) and 42.00% below its 200-day moving average ($2.50). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GRI overbought or oversold?
At the October 20, 2026 close, GRI's RSI(14) was 18.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $10.9M in cash comfortably exceeding the $44K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$6.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -142.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -0.61 suggests GRI is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GRI Bio, Inc.'s trajectory.